• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

给药间隔对庆大霉素和替卡西林在粒细胞减少小鼠中抗铜绿假单胞菌活性的影响。

Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.

作者信息

Gerber A U, Craig W A, Brugger H P, Feller C, Vastola A P, Brandel J

出版信息

J Infect Dis. 1983 May;147(5):910-7. doi: 10.1093/infdis/147.5.910.

DOI:10.1093/infdis/147.5.910
PMID:6842025
Abstract

The influence of dosing intervals on the activity of gentamicin and ticarcillin against Pseudomonas aeruginosa was studied in vivo. Granulocytopenic mice infected with P. aeruginosa in the thigh muscle were treated with 1-hr or 3-hr injections of gentamicin, ticarcillin, or gentamicin-ticarcillin. Plasma pharmacokinetics of the drugs were correlated with antibacterial activity. Gentamicin injected every 1 hr tended to be less active than gentamicin injected at longer intervals. In contrast, ticarcillin given every 1 hr was significantly more efficacious than equivalent total doses injected every 3 hr. The dosing schedule of gentamicin-ticarcillin was again important for ticarcillin but did not appreciably affect the antibacterial activity of gentamicin. Thus, antimicrobial chemotherapy of P. aeruginosa infections in the granulocytopenic host might be improved by administering ticarcillin rather than gentamicin as a constant infusion.

摘要

在体内研究了给药间隔对庆大霉素和替卡西林抗铜绿假单胞菌活性的影响。用铜绿假单胞菌感染大腿肌肉的粒细胞减少小鼠,分别给予1小时或3小时注射庆大霉素、替卡西林或庆大霉素-替卡西林。药物的血浆药代动力学与抗菌活性相关。每1小时注射一次的庆大霉素活性往往低于间隔较长时间注射的庆大霉素。相比之下,每1小时给予的替卡西林比每3小时注射同等总剂量的替卡西林显著更有效。庆大霉素-替卡西林的给药方案对替卡西林仍然很重要,但对庆大霉素的抗菌活性没有明显影响。因此,通过持续输注给予替卡西林而非庆大霉素,粒细胞减少宿主中铜绿假单胞菌感染的抗菌化疗可能会得到改善。

相似文献

1
Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.给药间隔对庆大霉素和替卡西林在粒细胞减少小鼠中抗铜绿假单胞菌活性的影响。
J Infect Dis. 1983 May;147(5):910-7. doi: 10.1093/infdis/147.5.910.
2
Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.铜绿假单胞菌感染在正常小鼠和粒细胞缺乏小鼠中的抗生素治疗:鼠类与人药代动力学的比较
J Infect Dis. 1986 Jan;153(1):90-7. doi: 10.1093/infdis/153.1.90.
3
Pseudomonas peritonitis in neutropenic rats treated with amikacin, ceftazidime and ticarcillin, alone and in combination.用阿米卡星、头孢他啶和替卡西林单独及联合治疗的中性粒细胞减少大鼠的假单胞菌腹膜炎。
J Antimicrob Chemother. 1987 Jun;19(6):807-14. doi: 10.1093/jac/19.6.807.
4
Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin.囊性纤维化患者肺部感染的治疗:替卡西林与庆大霉素的对比研究
J Pediatr. 1977 Jan;90(1):144-8. doi: 10.1016/s0022-3476(77)80790-7.
5
The impact of the pre-treatment interval on antimicrobial efficacy in a biological model.生物模型中预处理间隔对抗菌疗效的影响。
J Antimicrob Chemother. 1993 May;31 Suppl D:29-39. doi: 10.1093/jac/31.suppl_d.29.
6
Ticarcillin in the treatment of experimental pseudomonas keratitis.替卡西林治疗实验性铜绿假单胞菌角膜炎
Br J Ophthalmol. 1977 Feb;61(2):92-5. doi: 10.1136/bjo.61.2.92.
7
Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats.阿洛西林、替卡西林、阿米卡星单药治疗以及β-内酰胺类/阿米卡星联合治疗对粒细胞缺乏大鼠铜绿假单胞菌血症的疗效。
Am J Med. 1986 May 30;80(5C):53-8.
8
Experimental Pseudomonas aeruginosa sepsis: absence of synergy between ticarcillin and tobramycin.实验性铜绿假单胞菌败血症:替卡西林与妥布霉素之间缺乏协同作用。
J Lab Clin Med. 1983 Mar;101(3):441-9.
9
Ticarcillin in combination with cephalothin or gentamicin as empiric antibiotic therapy in granulocytopenic cancer patients.替卡西林联合头孢噻吩或庆大霉素作为粒细胞减少癌症患者的经验性抗生素治疗。
Antimicrob Agents Chemother. 1976 Nov;10(5):837-44. doi: 10.1128/AAC.10.5.837.
10
Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis.替卡西林与羧苄西林治疗囊性纤维化患者支气管肺感染加重期的比较。
Br J Dis Chest. 1983 Apr;77(2):179-84. doi: 10.1016/0007-0971(83)90025-6.

引用本文的文献

1
In vivo pharmacokinetic and pharmacodynamic profiles of orbifloxacin against Staphylococcus aureus in a neutropenic murine thigh infection model.在中性粒细胞减少小鼠大腿感染模型中,奥比沙星对金黄色葡萄球菌的体内药代动力学和药效学特征。
BMC Vet Res. 2025 Aug 29;21(1):531. doi: 10.1186/s12917-025-04974-8.
2
Rational design of a new antibiotic class for drug-resistant infections.针对耐药性感染的新型抗生素类药物的合理设计。
Nature. 2021 Sep;597(7878):698-702. doi: 10.1038/s41586-021-03899-0. Epub 2021 Sep 15.
3
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
用于治疗多重耐药菌引起的新生儿败血症的潜在抗生素
Paediatr Drugs. 2021 Sep;23(5):465-484. doi: 10.1007/s40272-021-00465-z. Epub 2021 Aug 26.
4
Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.通过将新型靶位渗透和受体结合分析平台整合到转化模型中,来对抗多药耐药菌。
Clin Pharmacol Ther. 2021 Apr;109(4):1000-1020. doi: 10.1002/cpt.2205. Epub 2021 Mar 24.
5
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.发现一种可口服的 A、C 和 D 类丝氨酸β-内酰胺酶的二氮杂双环辛烷抑制剂(ETX0282)。
J Med Chem. 2020 Nov 12;63(21):12511-12525. doi: 10.1021/acs.jmedchem.0c00579. Epub 2020 Jul 24.
6
Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.哌拉西林-他唑巴坦时间超过 MIC 对铜绿假单胞菌菌血症结局的预测作用。
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.02571-19.
7
Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282.β-内酰胺酶抑制剂ETX1317及其口服可用前药ETX0282的药代动力学/药效学测定及临床前药代动力学
ACS Infect Dis. 2020 Jun 12;6(6):1378-1388. doi: 10.1021/acsinfecdis.0c00019. Epub 2020 May 14.
8
Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR).β-内酰胺类抗生素在危重症患者中的治疗优化:法国药理学和治疗学学会(Société Française de Pharmacologie et Thérapeutique-SFPT)和法国麻醉与重症监护医学学会(Société Française d'Anesthésie et Réanimation-SFAR)的指南。
Crit Care. 2019 Mar 29;23(1):104. doi: 10.1186/s13054-019-2378-9.
9
Identification of the Pharmacokinetics and Pharmacodynamic Driver of Iclaprim.依拉菌素的药代动力学和药效学驱动因素的鉴定。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02550-17. Print 2018 Apr.
10
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.ETX2514 是一种广谱β-内酰胺酶抑制剂,用于治疗包括鲍曼不动杆菌在内的耐药革兰氏阴性菌。
Nat Microbiol. 2017 Jun 30;2:17104. doi: 10.1038/nmicrobiol.2017.104.